713
Views
6
CrossRef citations to date
0
Altmetric
Editorial

Evaluating a novel treatment for coronary artery inflammation in acute Kawasaki disease: a Phase I/IIa trial of atorvastatin

, MD MAS (Associate Professor, Associate Director) , , PhD (Professor, Co-Director) & , MD (Professor, Director)

Bibliography

  • Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324(23):1633-9
  • Takahashi K, Oharaseki T, Yokouchi Y, et al. Kawasaki disease: basic and pathological findings. Clin Exp Nephrol 2012
  • Gordon JB, Kahn AM, Burns JC. When children with kawasaki disease grow up myocardial and vascular complications in adulthood. J Am Coll Cardiol 2009;54(21):1911-20
  • Daniels LB, Tjajadi MS, Walford HH, et al. Prevalence of Kawasaki disease in young adults with suspected myocardial ischemia. Circulation 2012;125(20):2447-53
  • Mihos CG, Salas MJ, Santana O. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review. Cardiol Rev 2010;18(6):298-304
  • Shimizu C, Matsubara T, Onouchi Y, et al. Matrix metalloproteinase haplotypes associated with coronary artery aneurysm formation in patients with Kawasaki disease. J Hum Genet 2010;55(12):779-84
  • Blankier S, McCrindle BW, Ito S, Yeung RS. The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease. Clin Exp Immunol 2011;164(2):193-201
  • Izidoro-Toledo TC, Guimaraes DA, Belo VA, et al. Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells. Naunyn Schmiedebergs Arch Pharmacol 2011;383(6):547-54
  • Franco A, Touma R, Song Y, et al. Specificity of regulatory T cells that modulate vascular inflammation. Autoimmunity 2014;47(2):95-104
  • Tang TT, Song Y, Ding YJ, et al. Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis. J Lipid Res 2011;52(5):1023-32
  • Shimizu C, Jain S, Davila S, et al. Transforming growth factor-beta signaling pathway in patients with Kawasaki disease. Circ Cardiovasc Genet 2011;4(1):16-25
  • Shimizu C, Oharaseki T, Takahashi K, et al. The role of TGF-beta and myofibroblasts in the arteritis of Kawasaki disease. Hum Pathol 2013;44(2):189-98
  • Turner NA, Aley PK, Hall KT, et al. Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms. J Mol Cell Cardiol 2007;43(2):168-76
  • Storer BE. Design and analysis of phase I clinical trials. Biometrics 1989;45(3):925-37
  • Niedra E, Chahal N, Manlhiot C, et al. Atorvastatin safety in Kawasaki disease patients with coronary artery aneurysms. Pediatr Cardiol 2014;35(1):89-92
  • Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012;379(9826):1613-20

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.